Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug245 | Alcohol Wiki | 1.00 |
| drug3301 | Reference Treatment- BMS-986165-01 Wiki | 1.00 |
| drug1508 | Famotidine Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth as various solid tablet prototypes, by healthy participants.
Description: Part A, B, C
Measure: Area under the plasma concentration-time curve from time zero to t (AUC (0-t)) of BMS-986165 Time: Day 1 and Day 7Description: QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)Description: QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)Description: The QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)Description: PR interval is the time from the onset of the P wave to the start of the QRS complex
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports